SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Exagen Inc. – ‘10-K’ for 12/31/19 – ‘EX-10.36’

On:  Wednesday, 3/25/20, at 5:17pm ET   ·   For:  12/31/19   ·   Accession #:  1274737-20-26   ·   File #:  1-39049

Previous ‘10-K’:  None   ·   Next:  ‘10-K’ on 3/16/21 for 12/31/20   ·   Latest:  ‘10-K’ on 3/18/24 for 12/31/23   ·   8 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/25/20  Exagen Inc.                       10-K       12/31/19   88:11M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.33M 
 2: EX-10.27    Material Contract                                   HTML     29K 
 3: EX-10.28    Material Contract                                   HTML     33K 
 4: EX-10.29    Material Contract                                   HTML     53K 
 5: EX-10.31    Material Contract                                   HTML     32K 
 6: EX-10.32    Material Contract                                   HTML     87K 
 7: EX-10.33    Material Contract                                   HTML    269K 
 8: EX-10.36    Material Contract                                   HTML     59K 
 9: EX-10.41    Material Contract                                   HTML     28K 
10: EX-23.1     Consent of Experts or Counsel                       HTML     25K 
11: EX-31.1     Certification -- §302 - SOA'02                      HTML     31K 
12: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
13: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
28: R1          Cover                                               HTML     91K 
62: R2          Condensed Balance Sheets                            HTML     98K 
85: R3          Unaudited Condensed Statements of Operations        HTML     79K 
40: R4          Unaudited Condensed Statements of Redeemable        HTML    111K 
                Convertible Preferred Stock and Stockholders'                    
                Equity                                                           
27: R5          Statements of Cash Flows                            HTML    142K 
61: R6          Unaudited Condensed Statements of Redeemable        HTML     32K 
                Convertible Preferred Stock and Stockholders'                    
                Equity (Deficit) (Parenthetical)                                 
84: R7          Condensed Balance Sheets - (Parenthetical)          HTML     66K 
38: R8          Statement of Cash Flows (Parenthetical)             HTML     26K 
29: R9          Organization - (Notes)                              HTML     35K 
71: R10         Summary Of Significant Accounting Policies -        HTML    147K 
                (Notes)                                                          
80: R11         Other Financial Information - (Notes)               HTML     81K 
52: R12         Borrowings - (Notes)                                HTML     49K 
22: R13         Warrants to Purchase Common or Preferred Stock -    HTML     45K 
                (Notes)                                                          
72: R14         Commitment and Contingencies - (Notes)              HTML     52K 
81: R15         Fair Value Measurements - (Notes)                   HTML     65K 
53: R16         Redeemable Convertible Preferred Stock              HTML     39K 
23: R17         Stockholders' Equity (Deficit)                      HTML     30K 
73: R18         Stock Option Plan                                   HTML     87K 
79: R19         Income Taxes                                        HTML    102K 
42: R20         Related Parties                                     HTML     31K 
30: R21         401(k) Plan                                         HTML     27K 
58: R22         Subsequent Events                                   HTML     30K 
82: R23         Summary Of Significant Accounting Policies -        HTML    107K 
                Policies                                                         
43: R24         Summary Of Significant Accounting Policies -        HTML    119K 
                (Tables)                                                         
31: R25         Other Financial Information - (Tables)              HTML     84K 
59: R26         Borrowings - (Tables)                               HTML     38K 
83: R27         Warrants to Purchase Common or Preferred Stock -    HTML     44K 
                (Tables)                                                         
41: R28         Commitment and Contingencies (Tables)               HTML     65K 
32: R29         Fair Value Measures and Disclosures (Tables)        HTML     67K 
26: R30         Stock Option Plan (Tables)                          HTML     90K 
56: R31         Income Taxes (Tables)                               HTML    103K 
78: R32         Organization - (Details)                            HTML     51K 
70: R33         Summary Of Significant Accounting Policies -        HTML     52K 
                Narrative (Details)                                              
25: R34         Summary Of Significant Accounting Policies -        HTML     52K 
                Revenue by Major Payers (Details)                                
54: R35         Summary Of Significant Accounting Policies -        HTML     38K 
                Disaggregation of Revenue (Details)                              
77: R36         Summary Of Significant Accounting Policies - Cash,  HTML     35K 
                cash equivalents and restricted cash (Details)                   
69: R37         Summary Of Significant Accounting Policies -        HTML     36K 
                Securities (Details)                                             
24: R38         Other Financial Information - Narrative (Details)   HTML     32K 
57: R39         Other Financial Information - Prepaid expenses      HTML     38K 
                (Details)                                                        
36: R40         Other Financial Information - Property and          HTML     45K 
                equipment (Details)                                              
45: R41         Other Financial Information - Accrued liabilities   HTML     48K 
                (Details)                                                        
88: R42         Borrowings - Narrative (Details)                    HTML     78K 
66: R43         Borrowings - Future minimum payments (Details)      HTML     49K 
34: R44         Warrants to Purchase Common or Preferred Stock -    HTML     36K 
                Narrative (Details)                                              
44: R45         Warrants to Purchase Common or Preferred Stock -    HTML     40K 
                Outstanding warrants (Details)                                   
87: R46         Commitment and Contingencies - Narrative (Details)  HTML     55K 
65: R47         Commitment and Contingencies - Minimum annual       HTML     69K 
                lease payments under non-cancelable lease                        
                arrangements (Details)                                           
33: R48         Fair Value Measurements - Fair value measurement    HTML     45K 
                (Details)                                                        
46: R49         Fair Value Measurements- Fair value level 3         HTML     42K 
                (Details)                                                        
49: R50         Redeemable Convertible Preferred Stock (Details)    HTML     83K 
19: R51         Stockholders' Equity (Deficit) (Details)            HTML     49K 
67: R52         Stock Option Plan - Narrative (Details)             HTML     71K 
74: R53         Stock Option Plan - Stock Option Activity           HTML     83K 
                (Details)                                                        
51: R54         Stock Option Plan - Fair Value Assumptions          HTML     46K 
                (Details)                                                        
20: R55         Stock Option Plan - Stock-Based Compensation        HTML     34K 
                Expense (Details)                                                
68: R56         Stock Option Plan - Common Stock Reserved For       HTML     35K 
                Future Issuance (Details)                                        
75: R57         Income Taxes (Details)                              HTML     39K 
48: R58         Income Taxes - Components of Income Tax Expense     HTML     48K 
                (Benefit) (Details)                                              
21: R59         Income Taxes - Reconciliation of Effective Income   HTML     47K 
                Tax Rate (Details)                                               
63: R60         Income Taxes - Reconciliation of Deferred Tax       HTML     61K 
                Assets and Liabilities (Details)                                 
86: R61         Income Taxes - Change In Valuation Allowance        HTML     31K 
                (Details)                                                        
47: R62         Related Parties (Details)                           HTML     45K 
37: R63         401(k) Plan (Details)                               HTML     28K 
64: R64         Subsequent Events (Details)                         HTML     42K 
39: R9999       Uncategorized Items - exdx-20191231.htm             HTML     25K 
55: XML         IDEA XML File -- Filing Summary                      XML    147K 
35: XML         XBRL Instance -- exdx-20191231_htm                   XML   1.84M 
50: EXCEL       IDEA Workbook of Financial Reports                  XLSX     87K 
15: EX-101.CAL  XBRL Calculations -- exdx-20191231_cal               XML    235K 
16: EX-101.DEF  XBRL Definitions -- exdx-20191231_def                XML    679K 
17: EX-101.LAB  XBRL Labels -- exdx-20191231_lab                     XML   1.77M 
18: EX-101.PRE  XBRL Presentations -- exdx-20191231_pre              XML   1.03M 
14: EX-101.SCH  XBRL Schema -- exdx-20191231                         XSD    172K 
76: JSON        XBRL Instance as JSON Data -- MetaLinks              364±   562K 
60: ZIP         XBRL Zipped Folder -- 0001274737-20-000026-xbrl      Zip    733K 


‘EX-10.36’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  


Exhibit 10.36

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT

This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this Agreement”) is entered into as of November 19, 2019, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership (together with its successors and assigns, “Innovatus”), as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof or otherwise a party thereto from time to time (each a “Lender” and collectively, “Lenders”), and EXAGEN INC., a Delaware corporation (f/k/a EXAGEN DIAGNOSTICS, INC.) (“Borrower”).

Recitals
A. Collateral Agent, Lenders, and Borrower have entered into that certain Loan and Security Agreement dated as of September 7, 2017 (as the same may from time to time be amended, modified, supplemented or restated, the “Loan Agreement”).
B. Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.
C. Borrower has requested that Collateral Agent and Lenders amend the Loan Agreement as more fully set forth herein.
D. Collateral Agent and Lenders have agreed to amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.
E. As of the date hereof, the outstanding principal balance of the Term Loans, including payable in-kind interest which has been capitalized, is $26,161,884.94 (See Annex X).
Agreement
        Now, Therefore, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:
1.Definitions. Capitalized terms used but not defined in this Agreement shall have the meanings given to them in the Loan Agreement.
2.Amendments.
2.1 Section 2.2 (Term Loans). Section 2.2(b) of the Loan Agreement is amended and restated as follows:
(b) Repayment. Borrower shall make monthly payments of interest only commencing on the second (2nd) Payment Date following the Funding Date of the Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of the Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date after such Funding Date. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal,





plus interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to twenty-four (24) months. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on the Maturity Date. The Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).

2.2 Section 2.2 (Term Loans). Section 2.2(d) of the Loan Agreement is amended and restated as follows:
(d) Permitted Prepayment of Term Loan. After the first anniversary of the First Amendment Effective Date only, Borrower shall have the option to prepay all or part of the Term Loan advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loan at least five (5) days prior to such prepayment, (ii) in the event of a partial prepayment, prepays such part of the Term Loan in a denomination that is a whole number multiple of Five Million Dollars ($5,000,000.00), and (iii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) the portion of outstanding principal of the Term Loan being prepaid plus all accrued and unpaid interest thereon through the prepayment date, (B) the applicable Final Payment with respect to the portion of the Term Loan being prepaid, (C) all other Obligations that are then due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts pursuant to the terms of this Agreement, and (D) the applicable Prepayment Fee with respect to the portion of the Term Loan being prepaid. For the sake of clarity, any partial prepayment shall be applied pro-rata to all outstanding amounts under the Term Loan, and shall be applied on a pro-rata basis to all remaining payments outstanding in inverse order of maturity.

2.3 Section 2.3 (Payment of Interest on the Term Loan). Section 2.3(a) of the Loan Agreement is amended and restated as follows:
(a) Interest Rate. Subject to Section 2.3(b), the principal amount outstanding under the Term Loan shall accrue interest at a fixed per annum rate equal to eight and one-half percent (8.50%), which interest shall be payable monthly in arrears in accordance with Sections 2.2(b) and 2.3(e); provided that two percent (2.00%) of such eight and one-half percent (8.50%) interest rate shall be payable in-kind through the Amortization Date by adding an amount equal to such two percent (2.00%) interest to the then outstanding principal balance on a monthly basis so as to increase the outstanding principal balance of such Term Loan on each Payment Date and which amount shall be payable when the principal amount of the Term Loan is payable in accordance with Sections 2.2(b) and 2.3(e) and on which principal amount interest shall be owed pursuant to Section 2.3(a).

2.4 Section 6.11 (Minimum Liquidity). Section 6.11 of the Loan Agreement is amended and restated as follows:
6.11 Minimum Liquidity. Borrower shall at all times maintain minimum unrestricted cash and Cash Equivalents, in an account subject to a control agreement in favor of Collateral Agent, in an amount equal to Two Million Dollars ($2,000,000.00).

2.5 Section 6.15 (Performance to Plan). A new Section 6.15 is added to the Loan Agreement as follows:
6.15 Performance to Plan. So long as the Performance Period is not in effect, Borrower shall achieve minimum trailing twelve (12) month revenue under GAAP,




measured at the end of each calendar quarter commencing with the quarter ending December 31, 2019, greater than seventy percent (70%) of projected revenue under GAAP (such projections attached hereto as Annex Q, the “Management Plan”) (the “Performance Covenant”). Borrower’s failure to maintain the Performance Covenant may be cured by the Equity Cure. Upon the Equity Cure, the Performance Covenant shall be based on the New Management Plan.

2.6 Section 8.2 (Covenant Default). Section 8.2(a) of the Loan Agreement is amended and restated as follows:
(a) Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.11 (Minimum Liquidity), 6.15 (Performance to Plan) or Borrower violates any provision in Section 7; or

2.7 Section 13 (Definitions). The following terms and their definition are added to or amended and restated in Section 13 of the Loan Agreement as follows:
Amortization Date” is the thirty-seventh (37th) Payment Date following the First Amendment Effective Date.

Cash Flow” is an amount equal to (i) Borrower’s cash flow from operations, minus (ii) Borrower’s capital expenditures.

Equity Cure” means Borrower’s receipt, within sixty (60) days (or such longer period as acceptable to Collateral Agent and Innovatus in their sole reasonable discretion based on Borrower’s good faith efforts to complete the Equity Cure) of any failure to achieve the Performance Covenant, of gross proceeds from the sale and issuance of Borrower’s equity securities or Subordinated Debt, which in each case will not have any redemption, clawback, escrow or similar terms of at least an amount necessary for Borrower to achieve Cash Flow of at least Zero Dollars ($0) prior to the Maturity Date based on a new management plan provided by the Borrower (the “New Management Plan”), which is subject to Collateral Agent’s and Innovatus’ approval in their sole reasonable discretion.

First Amendment Effective Date” is November 19, 2019.

Maturity Date” is November 19, 2024.

Performance Period” is, provided no Event of Default has occurred and is continuing, the period (a) commencing on the day that Borrower provides to Collateral Agent and Lenders a written report that (i) Borrower has achieved trailing twelve (12) month revenue under GAAP of at least One Hundred Million Dollars ($100,000,000.00), and (ii) Borrower has been cash flow positive for at least two (2) consecutive quarters (collectively, the “Performance Requirement”), and (b) terminating on the earlier to occur of (i) the occurrence of an Event of Default, and (ii) the first day thereafter in which Borrower fails to maintain the Performance Requirement as disclosed in any Compliance Certificate.

Prepayment Fee” is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, as indicated, an additional fee payable to the Lenders in amount equal to:





(i) for any prepayment made after the First Amendment Effective Date through and including the first anniversary of the First Amendment Effective Date, which, pursuant to Section 2.2(d), may not be a voluntary prepayment, three percent (3.00%) of the principal amount of the Term Loan prepaid;

(ii) for any prepayment made after the first anniversary of the First Amendment Effective Date through and including the second anniversary of the First Amendment Effective Date, two percent (2.00%) of the principal amount of the Term Loan prepaid;

(iii) for any prepayment made after the second anniversary of the First Amendment Effective Date through and including the third anniversary of the First Amendment Effective Date, one percent (1.00%) of the principal amount of the Term Loan prepaid; and

(iv) for any prepayment made after the third anniversary of the First Amendment Effective Date, zero percent (0%) of the principal amount of the Term Loan prepaid.

2.8 Section 13 (Definitions). The following terms and their definitions are deleted in their entirety from Section 13 of the Loan Agreement:
Gross Margin”; “Gross Profit”; Interest-Only Milestones”; “I/O Gross Margin Milestone”; “I/O Gross Profit Milestone”; “I/O Revenue Milestone”; “Permitted Prepayment Mandatory Warrant”; “Permitted Prepayment Reason”; “Prepayment Mandatory Fee”.

2.9 Exhibit C (Compliance Certificate) to the Loan Agreement is replaced with Exhibit C attached hereto.
2.10 Annex Q (Management Plan) to the Loan Agreement is replaced with Annex Q attached hereto.
2.11 Annex X (Loan Interest Rate and Payment of Principal Schedule) attached hereto is added to the Loan Agreement.
2.12 Schedule I (Prepayment Mandatory Fee) to the Loan Agreement is deleted in its entirety.
3.Limitation of Agreement.
3.1 This Agreement is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent and Lenders may now have or may have in the future under or in connection with any Loan Document.
3.2 This Agreement shall be construed in connection with and as part of the Loan Documents, and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.
4.Representations and Warranties. Borrower represents and warrants to Collateral Agent and Lenders as follows:




4.1 (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing immediately before and after giving effect to this Agreement;
4.2 Borrower has the power and authority to execute and deliver this Agreement and to perform its obligations under the Loan Agreement;
4.3 The organizational documents of Borrower delivered to Collateral Agent and Lenders on the Effective Date or subsequent thereto remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;
4.4 The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement have been duly authorized by all necessary action on the part of Borrower;
4.5 The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;
4.6 The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on either Borrower, except as already has been obtained or made; and
4.7 This Agreement has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.
5.Prior Agreement. The Loan Documents are hereby ratified and reaffirmed and shall remain in full force and effect. This Agreement is not a novation and the terms and conditions of this Agreement shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. In the event of any conflict or inconsistency between this Agreement and the terms of such documents, the terms of this Agreement shall be controlling, but such document shall not otherwise be affected or the rights therein impaired.
6.Integration. This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.
7.Counterparts. This Agreement may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.
8.Conditions to Effectiveness. This Agreement shall be deemed effective upon the due execution and delivery to Collateral Agent and Lenders, in form and substance reasonably satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary or appropriate (and requested in writing at least three Business Days prior to the date hereof), including, without limitation:




a)  this Agreement duly executed by each party hereto;
b) a duly executed corporate borrowing certificate dated as of the date hereof; and
c) Borrower’s payment of all Lenders’ Expenses incurred through the date of this Agreement to the extent due and payable pursuant to Sections 2.4(d) or 12.2 of the Loan Agreement, which amount for the documentation and negotiation of this Agreement shall not exceed Fifteen Thousand Dollars ($15,000).
9.Miscellaneous.
9.1 This Agreement shall constitute a Loan Document under the Loan Agreement; the failure to comply with the covenants contained herein shall constitute an Event of Default under the Loan Agreement; and all obligations included in this Agreement (including, without limitation, all obligations for the payment of principal, interest, fees, and other amounts and expenses) shall constitute obligations under the Loan Agreement and secured by the Collateral.
9.2 Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.
10.Governing Law. This Agreement and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.
[Signature pages follow.]





IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above.

BORROWER:





EXAGEN INC.












Title: Chief Financial Officer











































IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above.

COLLATERAL AGENT AND LENDER:





INNOVATUS LIFE SCIENCES LENDING FUND I, LP



Its: General Partner



By: /s/ Andrew Hobson 




Title: Authorized Signatory









EXHIBIT C

Compliance Certificate





ANNEX Q
(Management Plan)






ANNEX X

(Loan Interest Rate and Payment of Principal Schedule)









Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
11/19/24
Filed on:3/25/208-K
For Period end:12/31/19
11/19/198-K
9/7/17
 List all Filings 


8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/18/24  Exagen Inc.                       10-K       12/31/23   76:8.9M
 5/04/23  Exagen Inc.                       8-K:1,2,9   4/28/23   11:241K
 3/20/23  Exagen Inc.                       10-K       12/31/22   76:9.1M
 3/22/22  Exagen Inc.                       10-K       12/31/21   73:8.6M                                   Workiva Inc Wde… FA01/FA
 4/01/21  Exagen Inc.                       10-K/A     12/31/20   14:498K
 3/23/21  Exagen Inc.                       424B5                  1:601K                                   Donnelley … Solutions/FA
 3/22/21  Exagen Inc.                       424B5                  1:599K                                   Donnelley … Solutions/FA
 3/16/21  Exagen Inc.                       10-K       12/31/20   78:8.7M
Top
Filing Submission 0001274737-20-000026   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 11:20:13.2pm ET